Cogent Biosciences Quarterly Income Statement
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.00+0.92 (+3.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences revenue and earnings
Cogent Biosciences reported a net loss of $96.4 million, compared with a loss of $73.5 million a year earlier. Diluted earnings per share came in at -$0.52.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development | 70.81M | 75.36M | 75.56M | 68.99M | 62.20M | 63.03M | 62.05M | 63.61M | 54.29M | 52.70M | 48.72M | 50.13M |
| Operating Income | -102.64M | -103.61M | -99.49M | -83.36M | -75.58M | -74.93M | -73.73M | -75.41M | -64.39M | -62.40M | -58.23M | -59.58M |
| Interest Expense | 1.22M | 1.21M | 1.29M | 1.46M | 314.00K | — | — | — | — | — | — | — |
| Other Income (Expense) | 6.23M | 6.25M | -3.00M | 2.42M | 2.05M | 2.95M | 5.81M | 4.78M | 5.44M | 4.06M | 3.86M | 4.20M |
| Net Income | -96.41M | -97.35M | -102.49M | -80.93M | -73.53M | -71.99M | -67.93M | -70.63M | -58.95M | -58.35M | -54.37M | -55.38M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.52 | -0.53 | -0.61 | -0.50 | -0.53 | -0.52 | -0.50 | -0.52 | -0.43 | -0.49 | -0.16 | -0.64 |
| EPS (Diluted) | -0.52 | -0.53 | -0.61 | -0.50 | -0.53 | -0.52 | -0.50 | -0.52 | -0.43 | -0.49 | -0.16 | -0.64 |
| Shares Outstanding (Basic) | 171.01M | 162.19M | — | 137.55M | 114.47M | 113.31M | — | 110.17M | 99.24M | 94.80M | — | 86.17M |
| Shares Outstanding (Diluted) | 171.01M | 162.19M | — | 137.55M | 114.47M | 113.31M | — | 110.17M | 99.24M | 94.80M | — | 86.17M |
| EBITDA | -101.90M | -102.98M | -98.83M | -82.71M | -74.93M | -74.29M | -73.06M | -74.79M | -63.78M | -61.80M | -57.60M | -59.00M |
This table shows 12 quarterly periods of Cogent Biosciences's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow COGT's reporting calendar. What is a income statement?